Abstract
We have recently described a novel mRNA denominated ScRG-1, the level of which is increased in the brains of Scrapie-infected mice (Dandoy-Dron, F., Guillo, F., Benboudjema, L., Deslys, J.-P., Lasmézas, C., Dormont, D., Tovey, M. G., and Dron, M. (1998) J. Biol. Chem. 273, 7691-7697). The increase in ScRG-1 mRNA in the brain follows the accumulation of PrPSc, the proteinase K-resistant form of the prion protein (PrP), and precedes the widespread neuronal death that occurs in late stage disease. In the present study, we have isolated a cDNA encoding the human counterpart of ScRG-1. Comparison of the human and mouse transcripts firmly established that both sequences encode a highly conserved protein of 98 amino acids that contains a signal peptide, suggesting that the protein may be secreted. Examination of the distribution of human ScRG-1 mRNA in adult and fetal tissues revealed that the gene was expressed primarily in the central nervous system as a 0.7-kilobase message and was under strict developmental control.
Highlights
We have recently described a novel mRNA denominated scrapie-responsive gene 1 (ScRG-1), the level of which is increased in the brains of Scrapie-infected mice
We report the nucleotide sequence, size characterization, and tissue distribution of human ScRG-1 mRNA
To ascertain the existence of the human ScRG-1 mRNA, primers derived from the 5Ј and 3Ј ends of the consensus sequence were used to synthesize cDNA from human brain mRNA by specific reverse transcription and polymerase chain reaction amplification
Summary
We have recently described a novel mRNA denominated ScRG-1, the level of which is increased in the brains of Scrapie-infected mice The human cDNA contained an open reading frame (ORF) at positions 414 –710 encoding a protein exhibiting strong homology with the protein predicted from the murine ScRG-1 cDNA (Fig. 1B). The corrected nucleotide sequence of the mouse brain ScRG-1 cDNA and derived amino acid sequence (Fig. 1, A and B) have been reported in the data bases.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
